piperidin-4-yl(pyridin-3-yl)methanone hydrochloride | 416852-57-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: piperidin-4-yl(pyridin-3-yl)methanone hydrochloride
• 英文别名: Piperidin-4-yl-pyridin-3-yl-methanonehydrochloride；piperidin-4-yl(pyridin-3-yl)methanone;hydrochloride
• CAS: 416852-57-8
• 化学式: C₁₁H₁₄N₂O*ClH
• 分子量: 226.706
• InChiKey: VHMXLGUEKBKKGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.69
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  42
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  piperidin-4-yl(pyridin-3-yl)methanone hydrochloride 在 甲醇 、 sodium tetrahydroborate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 乙二胺四乙酸 、 potassium tert-butylate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 mercury(II) oxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 7.5h， 生成 1-(3,4-dichlorophenyl)-4-[hydroxy(3-pyridyl)methyl]piperidin-2-one
  参考文献：
  名称：

  [EN] AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS D'AZÉTIDINE ET DE SPIROAZÉTIDINE ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2021247916A8
• 作为产物：
  描述：

  3-吡啶溴化镁 在 盐酸 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 20.5h， 生成 piperidin-4-yl(pyridin-3-yl)methanone hydrochloride
  参考文献：
  名称：

  [EN] AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS D'AZÉTIDINE ET DE SPIROAZÉTIDINE ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2021247916A8

文献信息

• HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20140107097A1

  公开（公告）日：2014-04-17

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涵盖了Formula I的化合物，其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。该发明还涵盖了一种治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病为类风湿性关节炎或银屑病。该发明还涵盖了通过给哺乳动物施用至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。
• [EN] PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS QUINOLINYLES À LIAISON PHÉNYLE DE RAR-GAMMA-T
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015057203A1

  公开（公告）日：2015-04-23

  The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涵盖了Formula I的化合物。其中Formula I中：R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中有定义。该发明还涵盖了一种治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还涵盖了通过给予权利要求1中至少一种化合物的治疗有效量来调节哺乳动物中的RORγt活性的方法。
• PHENYL LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20150105404A1

  公开（公告）日：2015-04-16

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括以下式I的化合物：其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中定义。该发明还包括一种治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病为类风湿性关节炎或牛皮癣。该发明还包括通过给予至少一种权利要求1的化合物的治疗有效量来调节哺乳动物中RORγt活性的方法。
• AMIDE COMPOUNDS
  申请人：Kitamura Shuji

  公开号：US20120065196A1

  公开（公告）日：2012-03-15

  The present invention provides compounds represented by the formula (Ie): and the formula (If): wherein each symbol is as defined in the specification. According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

  本发明提供由式(Ie)和式(If)所表示的化合物，其中每个符号如规范中所定义。根据本发明，这些化合物具有DGAT抑制活性，并可用于预防、治疗或改善由DGAT高表达或高活化引起的疾病或病理学。
• Phenyl linked quinolinyl modulators of RORγt
  申请人：Janssen Pharmaceutica NV

  公开号：US09309222B2

  公开（公告）日：2016-04-12

  The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涉及公式I的化合物，其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。本发明还涉及一种治疗或改善综合症、障碍或疾病的方法，其中所述的综合症、障碍或疾病是类风湿性关节炎或银屑病。本发明还涉及一种通过给哺乳动物施用至少一种权利要求1的化合物的治疗有效量来调节RORγt活性的方法。